Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.34 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5708922 | 0.83 | POLG (0.48) | POLGPOLBP2RY6P2RY2P2RY4 | |
| SCHEMBL5615382 | 0.82 | NT5E (0.34) | POLBNT5E | |
| SCHEMBL6914072 | 0.75 | POLG (0.62) | POLGPOLBP2RY6P2RY2P2RY4 | |
| SCHEMBL28805006 | 0.74 | PDE3A (0.43) | POLB | |
| SCHEMBL6038233 | 0.74 | POLG (0.50) | POLGPOLBP2RY6P2RY2P2RY4 | |
| SCHEMBL10900419 | 0.72 | POLG (0.49) | POLGPOLBP2RY6P2RY2P2RY4 | |
| SCHEMBL597307 | 0.72 | POLG (0.49) | POLGPOLBP2RY6P2RY2P2RY4 | |
| SCHEMBL30134674 | 0.71 | POLG (0.46) | POLGPOLBP2RY6P2RY2P2RY4 | |
| SCHEMBL886859 | 0.70 | POLG (0.41) | POLGP2RY6P2RY2P2RY4 | |
| SCHEMBL6672414 | 0.70 | POLG (0.56) | POLGP2RY6P2RY2P2RY4NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678329-A4 | PRENATAL DIAGNOSIS USING CELL-FREE FETAL DNA IN AMNIOTIC FLUID | TUFTS NEW ENGLAND MEDICAL CT (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070212689-A1 | Prenatal Diagnosis Using Cell-Free Fetal DNA in Amniotic Fluid | NATIONAL INSTITUTES OF HEALTH | 2007-09-13 | — | — | US | disclosed |
| US-20070111233-A1 | Prenatal diagnosis using cell-free fetal DNA in amniotic fluid | NATIONAL INSTITUTES OF HEALTH | 2007-05-17 | — | — | US | disclosed |
| EP-1678329-A2 | PRENATAL DIAGNOSIS USING CELL-FREE FETAL DNA IN AMNIOTIC FLUID | Tufts-New England Medical Center (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005044086-A2 | PRENATAL DIAGNOSIS USING CELL-FREE FETAL DNA IN AMNIOTIC FLUID | TUFTS-NEW ENGLAND MEDICAL CENTER (US) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111233-A1 | Prenatal diagnosis using cell-free fetal DNA in amniotic fluid | BOD1L1, SMCHD1, ALPP | POLG 1437/4885POLB 574/4885P2RY6 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.